BioNexus Gene Lab logo

BGLC - BioNexus Gene Lab Share Price

$2.38 0.2  8.2%

Last Trade - 03/03/21

Sector
Healthcare
Size
Small Cap
Market Cap £270.0m
Enterprise Value £269.8m
Revenue £59.5k
Position in Universe 3783rd / 6643
Bullish
Bearish
Unlock BGLC Revenue
Momentum
Relative Strength (%)
1m -7.23%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.11 0.21 0.13 +8.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,BioNexus Gene Lab Coporation revenues decreased 59% to$30K. Net loss increased 13% to $175K. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Other Income decrease of 46% to $11K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BGLC Revenue Unlock BGLC Revenue

Net Income

BGLC Net Income Unlock BGLC Revenue

Normalised EPS

BGLC Normalised EPS Unlock BGLC Revenue

PE Ratio Range

BGLC PE Ratio Range Unlock BGLC Revenue

Dividend Yield Range

BGLC Dividend Yield Range Unlock BGLC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BGLC EPS Forecasts Unlock BGLC Revenue
Profile Summary

BioNexus Gene Lab Corporation is a molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company is engaged in developing and marketing non-invasive blood tests for early detection of diseases. The Company’s non-invasive blood tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of over 11 different diseases. Bionexus Gene Lab Sdn. Bdh. is the subsidiary of the Company.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
No. of Shareholders: n/a
No. of Employees: 5
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 171,218,152
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BGLC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BGLC
Upcoming Events for BGLC
Frequently Asked Questions for BioNexus Gene Lab
What is the BioNexus Gene Lab share price?

As of 03/03/21, shares in BioNexus Gene Lab are trading at $2.38, giving the company a market capitalisation of £270.0m. This share price information is delayed by 15 minutes.

How has the BioNexus Gene Lab share price performed this year?

Shares in BioNexus Gene Lab are currently trading at $2.38 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioNexus Gene Lab price has moved by % over the past year.

What are the analyst and broker recommendations for BioNexus Gene Lab?

There are no analysts currently covering BioNexus Gene Lab.

When will BioNexus Gene Lab next release its financial results?

BioNexus Gene Lab is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioNexus Gene Lab dividend yield?

BioNexus Gene Lab does not currently pay a dividend.

Does BioNexus Gene Lab pay a dividend?

BioNexus Gene Lab does not currently pay a dividend.

When does BioNexus Gene Lab next pay dividends?

BioNexus Gene Lab does not currently pay a dividend.

How do I buy BioNexus Gene Lab shares?

To buy shares in BioNexus Gene Lab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioNexus Gene Lab?

Shares in BioNexus Gene Lab are currently trading at $2.38, giving the company a market capitalisation of £270.0m.

Where are BioNexus Gene Lab shares listed? Where are BioNexus Gene Lab shares listed?

Here are the trading details for BioNexus Gene Lab:

Country of listing: United States
Exchange: PNK
Ticker Symbol: BGLC
What kind of share is BioNexus Gene Lab?

Based on an overall assessment of its quality, value and momentum, BioNexus Gene Lab is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioNexus Gene Lab share price forecast 2021?

We were not able to load any forecast data for BioNexus Gene Lab.

How can I tell whether the BioNexus Gene Lab share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNexus Gene Lab. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $2.38, shares in BioNexus Gene Lab are trading at 7.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioNexus Gene Lab PE Ratio?

We were not able to find PE ratio data for BioNexus Gene Lab.

Who are the key directors of BioNexus Gene Lab?

We were unable to find the directors for BioNexus Gene Lab.

Who are the major shareholders of BioNexus Gene Lab?

Here are the top five shareholders of BioNexus Gene Lab based on the size of their shareholding:

Liew (Choong-Chin) Individual Investor
Percentage owned: 11.68% (20.0m shares)
Leong (Chi Yuen (George)) Individual Investor
Percentage owned: 8.76% (15.0m shares)
Lai (Soo Kow(kenny)) Individual Investor
Percentage owned: 8.76% (15.0m shares)
Wong (Chan Chong) Individual Investor
Percentage owned: 8.18% (14.0m shares)
Leong (Wei Li) Individual Investor
Percentage owned: 1.75% (3.00m shares)
Similar to BGLC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.